ImmunityBio shares rise 1.21% premarket after ANKTIVA treatment approval for bladder cancer.

Immunitybio, Inc. rose 1.21% in premarket trading, with the company announcing that the Michael E. DeBakey Department of Veterans Affairs (VA) Medical Center in Houston became the first VA hospital in the Houston region and one of the first in the U.S. to provide treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) to a veteran with bladder cancer. ANKTIVA, the first of its kind immune-boosting, lymphocyte stimulating agent, is approved by the U.S. Food and Drug Administration (FDA) in combination with Bacillus Calmette-Guerin (BCG) for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).